Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial (Q79839545)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author

Hans C. van Houwelingen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

C Grootscholten

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

G Ligtenberg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

E C Hagen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

A W L van den Wall Bake

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

J W de Glas-Vos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

M Bijl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

K J Assmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

J A Bruijn

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

J J Weening

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

R H W M Derksen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

J H M Berden

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Dutch Working Party on Systemic Lupus Erythematosus

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

5 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

732-742

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16820790%20AND%20SRC:MED&resulttype=core&format=json

Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

1 reference

7 January 2021

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Effect of treatment on the evolution of renal abnormalities in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Current treatment recommendations for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Treatment of proliferative lupus nephritis with methylprednisolone pulse therapy and oral azathioprine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Long-term efficacy of azathioprine treatment for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

The very long-term prognosis and complications of lupus nephritis and its treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Preventing renal failure in patients with severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Patient preferences for treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021

Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001630

7 January 2021